Monday, May 23, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study says duplilumab reduces mortality from COVID-19

by Medical Finance
in Coronavirus
Study: Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis​​​​​​​. Image Credit: Naeblys / Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus Disease 2019 (COVID-19), continues to plague the globe. Many approaches involve targeting inflammation to reduce mortality, such as using corticosteroids like dexamethasone and monoclonal antibodies like tocilizumab that target the cytokine IL-6. However, although these therapeutic options reduce mortality among patients, they do not provide 100% protection.

After a surge in the fatality rate (12.6%) by the Delta variant of SARS-CoV-2, lower mortality (7.3%) was recorded with the Omicron variant. Yet, the number of deaths remained high. This was because of the immune evasion ability of this variant of concern (VOC) and reduced vaccine efficacy against the variant.

A role of Interleukin-13 (IL-13) in severe infection outcomes of SARS-CoV-2 infection, including – increased smooth muscle contractility, mucus production, and immune cell recruitment, as well as airway remodeling, has been discovered recently. IL-13 has also been implicated in causing breathing difficulty and wheezing and decreased lung function and capacity in acute infection, explaining the disease’s long-term impact.

A monoclonal antibody, dupilumab, targets the IL-4Ra receptors, blocking the signaling of IL-4 and IL-13.

Study: Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis​​​​​​​. Image Credit: Naeblys / ShutterstockStudy: Dupilumab use is associated with protection from COVID-19 mortality: A retrospective analysis​​​​​​​. Image Credit: Naeblys / Shutterstock

The study

A recent report posted to the medRxiv* preprint server assessed the efficacy of dupilumab in blocking the IL-13 signaling pathway and its efficacy in reducing the COVID-19 associated mortality.

TriNetX and National COVID Cohort Collaborative (N3C) databases were used for this study. Participants were filtered from the N3C database based on the recorded COVID-19 positive test – either by positive SARS-CoV-2 polymerase chain reaction (PCR) test or positive antigen test—the first positive test marking the index date.

Participants were divided into three sub-cohorts – SARS-CoV-2 positive patients with no prior history of dupilumab use within 61 days pre-index date formed the control group; SARS-CoV-2 positive patients with prior history of dupilumab use within 61 days pre-index date formed the Dupilumab (+)ve group; and SARS-CoV-2 negative participants with prior dupilumab use formed the Dupilumab (-)ve group.

The incidence of SARS-CoV-2 positivity in participants who had taken dupilumab was calculated. The outcome ‘Hospitalized’ was defined as a positive SARS-CoV-2 test or diagnosis during hospitalization. ‘Death’ was defined from the record based on the contributing medical record system.

COVID-19 severity was categorized into four groups – the outpatients were marked ‘mild’; hospitalized patients with no extracorporeal membrane oxygenation (ECMO) or intermittent mandatory ventilation (IMV) were marked ‘moderate’; while hospitalized patients with ECMO or IMV were marked ‘severe’ and ‘death’.

Results

Out of the 1,069 patients taking prescribed dupilumab, 220 were diagnosed with SARS-CoV-2 infection within 61 days of taking dupilumab. It was found that Dupilumab (+)ve patients had significantly lower mortality than the control group.

Thereafter, the COVID-19 cases from the TriNetX database were categorized into – patients with recorded dupilumab use (937 and those without (1.7 million) and matched in the ratio of 1:1. It was noted that dupilumab reduced the risk of death compared to controls. Additionally, it was found that Dupilumab (+)ve cohort had lower C-reactive protein (CRP) values – suggesting lower inflammation in this group compared to the control group.

It was inferred that dupilumab usage was associated with higher survival rates compared to the control group. The findings support the causal role of IL-13 in the pathogenesis of COVID-19. It was hypothesized that dupilumab confers protection against SARS-CoV-2 by blocking the IL-13 signaling pathway. The datasets provide analyses supporting this hypothesis.

Conclusion

Dupilumab can be deemed a potent therapeutic option for treating SARS-CoV-2 infection, owing to its lowering effect on the disease severity and fatality rate of COVID-19 patients. The study proves the hypothesis that pharmacological inhibition of the IL-13 signaling pathway may be a therapeutic option against SARS-CoV-2 infection. Large-scale trials of dupilumab are warranted for determining its efficacy against severe outcomes of COVID-19 disease.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

Scrapping many Covid testing measures is a grave mistake, says London Medical Laboratory

by Medical Finance
May 23, 2022
0

London Medical Laboratory warns that its testing reveals nearly one in five people still have insufficient Covid antibodies. So why...

Study: Modelling the within-host spread of SARS-CoV-2 infection, and the subsequent immune response, using a hybrid, multiscale, individual-based model. Part I: Macrophages. Image Credit: MedMoMedia/Shutterstock

A hybrid, multiscale, individual-based model to study the within-host spread of SARS-CoV-2 and the subsequent innate immune response

by Medical Finance
May 22, 2022
0

Scientists have observed that every individual responds differently to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the causal agent of...

Travel nurses see swift change of fortunes as covid money runs dry

Travel nurses see swift change of fortunes as covid money runs dry

by Medical Finance
May 22, 2022
0

Jones, who has been a nurse for 17 years, caught up with a Facebook group for travel nurses and saw...

COVID-19 vaccines and reports of menstrual disorders

COVID-19 vaccines and reports of menstrual disorders

by Medical Finance
May 22, 2022
0

As of April 11, 2022, almost 500 million individuals around the world have been infected with the severe acute respiratory...

Study: Longitudinal analysis reveals elevation then sustained higher expression of autoantibodies for six months after SARS-CoV-2 infection. Image Credit:  Corona Borealis Studio/Shutterstock

Elevated and sustained autoantibodies following COVID-19

by Medical Finance
May 22, 2022
0

A recent study posted to the medRxiv* preprint server demonstrated that autoantibody levels rise following acute severe acute respiratory syndrome coronavirus...

Neurological complications of the SARS-CoV-2 vaccine

Neurological complications of the SARS-CoV-2 vaccine

by Medical Finance
May 22, 2022
0

In a study published in the latest issue of the journal Neurological Sciences, a team of researchers described a three-patient case...

Next Post
Study: Web and social media searches highlight menstrual irregularities as a global concern in COVID-19 vaccinations. Image Credit: 13_Phunkod / Shutterstock.com

The spread of menstrual irregularity and COVID-19 vaccines concerns on the web

Spice could play a key role in reducing salt intake among seniors

Spice could play a key role in reducing salt intake among seniors

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Intrinsic furin-mediated cleavability of the spike S1/S2 site from SARS-CoV-2 variant B.1.529 (Omicron). Image Credit: Naeblys/Shutterstock
    Evidence of increased intrinsic cleavability of SARS-CoV-2 Omicron spike protein by host cell furin
  • Study: A COVID-19 Vaccine for Dogs Prevents Reverse Zoonosis. Image Credit: LightField Studios/Shutterstock
    Canine COVID-19 vaccine could prevent reverse transmission of SARS-CoV-2
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply